Sartorius/€SRT3
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Sartorius
Sartorius AG, trading under the ticker symbol SRT3, is a global provider of laboratory and bioprocess technologies, offering products and services that cater to the needs of the biopharmaceutical and research industries. Founded in 1870 and headquartered in Göttingen, Germany, the company specializes in filtration, fermentation, fluid management, and laboratory products, supporting clients ranging from research facilities to large-scale biopharmaceutical manufacturers. Operating internationally, Sartorius is crucial in enabling the development and production of biotech medications and vaccines, solidifying its role as a crucial player in the life sciences and biotechnology sectors.
Ticker
€SRT3
Sector
Primary listing
XETRA
Employees
13,878
Headquarters
Website
Sartorius Metrics
BasicAdvanced
€15B
-
-
-
€0.74
0.31%
Price and volume
Market cap
€15B
52-week high
€292.00
52-week low
€166.05
Average daily volume
9.7K
Dividend rate
€0.74
Financial strength
Current ratio
0.95
Quick ratio
0.429
Long term debt to equity
89.312
Total debt to equity
111.952
Dividend payout ratio (TTM)
37.95%
Interest coverage (TTM)
2.88%
Profitability
EBITDA (TTM)
844.7
Gross margin (TTM)
46.48%
Net profit margin (TTM)
3.80%
Operating margin (TTM)
15.25%
Effective tax rate (TTM)
26.71%
Revenue per employee (TTM)
€250,000
Management effectiveness
Return on assets (TTM)
3.45%
Return on equity (TTM)
5.51%
Valuation
Dividend yield (TTM)
0.31%
Forward dividend yield
0.31%
Growth
Revenue change (TTM)
5.82%
3-year revenue growth (CAGR)
-4.48%
10-year revenue growth (CAGR)
12.57%
3-year dividend per share growth (CAGR)
-16.26%
10-year dividend per share growth (CAGR)
10.82%
What the Analysts think about Sartorius
Analyst ratings (Buy, Hold, Sell) for Sartorius stock.
Bulls say / Bears say
Bioprocess Solutions division sales rose 8.8% in constant currencies in H1 2025, driven by high-margin consumables, and the segment’s underlying EBITDA margin expanded to 31.6% on volume and mix benefits (Sartorius IR).
Group underlying EBITDA grew 11.9% to €527 million in H1 2025, with the margin improving to 29.8%, demonstrating operational efficiency and economies of scale (Sartorius IR).
Management reconfirmed full-year 2025 guidance for ~6% organic sales growth and a group underlying EBITDA margin of 29–30%, underscoring confidence in market resilience and execution (Sartorius IR).
Lab Products & Services division sales fell 4.0% in constant currencies in H1 2025, with underlying EBITDA margin contracting to 22.3%, reflecting persistent weakness in lab‐instrument demand (Sartorius IR).
Group Q2 2025 revenue of €884 million missed consensus by 1%, causing Sartorius shares to slide over 6% in European trading, highlighting sensitivity to minor sales shortfalls (Investing.com).
The rolling 12-month book-to-bill ratio eased to “above 1” in Q2 from “well above 1” in Q1, suggesting a moderation in order intake momentum despite remaining above the critical threshold (Investing.com).
Data summarised monthly by Lightyear AI. Last updated on 4 Oct 2025.
Sartorius Financial Performance
Revenues and expenses
Sartorius Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Sartorius stock?
Sartorius (SRT3) has a market cap of €15B as of October 24, 2025.
What is the P/E ratio for Sartorius stock?
The price to earnings (P/E) ratio for Sartorius (SRT3) stock is 0 as of October 24, 2025.
Does Sartorius stock pay dividends?
Yes, the Sartorius (SRT3) stock pays dividends to shareholders. As of October 24, 2025, the dividend rate is €0.74 and the yield is 0.31%. Sartorius has a payout ratio of 37.95% on a trailing twelve-month basis.
When is the next Sartorius dividend payment date?
The next Sartorius (SRT3) dividend payment date is unconfirmed.
What is the beta indicator for Sartorius?
Sartorius (SRT3) does not currently have a Beta indicator.